Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 2.97B 3.33B 2.77B 2.52B 4.74B 323B 4.79B 33.31B 13.03B 164B 12.5B 12.23B 527B P/E 2026 *
19.6x
P/E 2027 * 17.3x
Enterprise Value 2.97B 3.32B 2.77B 2.51B 4.73B 322B 4.77B 33.21B 12.99B 163B 12.47B 12.2B 526B EV / Sales 2026 *
3.83x
EV / Sales 2027 * 3.25x
Free-Float
31.63%
Yield 2026 *
1.67%
Yield 2027 * 2%
1 month-0.59%
3 months+4.73%
6 months-26.19%
Current year-1.74%
1 week 59.25
Extreme 59.25
59.25
1 month 59.25
Extreme 59.25
59.6
3 years 46.36
Extreme 46.36
90.3
5 years 35.3
Extreme 35.3
90.3
10 years 10.95
Extreme 10.95
90.3
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Operating Officer - -
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+0.81%+17.21% 3.33B
-1.61%+1.72%+38.30%+106.93% 1,043B
-0.76%-0.84%+35.21%+62.70% 618B
+0.39%+4.81%+17.81%+83.77% 481B
-0.29%-0.99%+64.79%+37.06% 351B
+1.26%+3.24%+21.56%+42.28% 338B
+0.82%+1.99%+11.29%+34.64% 269B
+1.05%+1.23%-7.14%+10.69% 244B
-1.37%+0.04%+38.29%+52.33% 220B
+0.17%-0.27%+24.40%+96.82% 182B
Average -0.02%+0.28%+24.53%+54.44% 416.3B
Weighted average by Cap. -0.33%+0.60%+30.53%+69.08%

Financials

2026 *2027 *
Net sales 774M 867M 722M 656M 1.23B 83.95B 1.25B 8.67B 3.39B 42.66B 3.25B 3.18B 137B 892M 999M 833M 756M 1.42B 96.79B 1.44B 10B 3.91B 49.18B 3.75B 3.67B 158B
Net income 146M 164M 136M 124M 233M 15.86B 235M 1.64B 641M 8.06B 615M 602M 25.92B 173M 194M 161M 147M 276M 18.75B 278M 1.94B 757M 9.53B 727M 711M 30.64B
Net Debt -8.5M -9.52M -7.93M -7.2M -13.55M -922M -13.69M -95.19M -37.23M -468M -35.74M -34.96M -1.51B -72.51M -81.2M -67.64M -61.44M -116M -7.86B -117M -812M -318M -4B -305M -298M -12.85B
Projected Income Statement - Annual - Laboratorios Farmaceuticos Rovi, S.A.
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
-
Date Price Change
08/10/26 €59.25 -3.03%
07/10/26 €61.10 0.00%
06/10/26 €61.10 0.00%
05/10/26 €61.10 0.00%
02/10/26 €61.10 0.00%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Laboratorios Farmaceuticos Rovi, S.A.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
58.15EUR
Average target price
74.36EUR
Spread / Average Target
+27.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Laboratorios Farmaceuticos Rovi, S.A.